Literature DB >> 9188856

Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells.

M Ivan1, J A Bond, M Prat, P M Comoglio, D Wynford-Thomas.   

Abstract

Hepatocyte Growth Factor (HGF) receptor, encoded by the protooncogene c-met, is overexpressed in many human tumours, including those of thyroid epithelium. The absence in most cases of any primary structural abnormality of the met gene suggests that overexpression is secondary to mutation of other gene(s). To test this hypothesis we investigated the effect on met expression of two activated oncogenes known to play a major role in thyroid oncogenesis, ras and ret. To minimize the possibility of unknown co-operating events, we introduced these genes directly into normal human thyrocytes in primary culture using amphotropic retroviral vectors and assessed met expression as early as possible in the resulting epithelial colonies. Double immunofluorescence revealed expression of met protein, strictly localized to cells expressing the mutant ras and ret vectors, expression in background normal cells being barely detectable. In contrast, colonies induced to proliferate at a comparable rate by a vector expressing SV40 T showed no increase in met expression. To permit quantitation by Western blotting we also extended these findings to a thyroid cell line (R18) containing a zinc-inducible mutant ras gene. Induction of the oncogene led to a fourfold increase in met protein expression. We conclude that overexpression of met is induced by activation of the ras or ret signalling pathway and not simply by deregulation of the cell cycle per se. The data suggest that the proliferative advantage conferred by these oncogenes may be in part due to the resulting sensitization of tumour epithelium to paracrine HGF secreted by stromal cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188856     DOI: 10.1038/sj.onc.1201083

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

Review 1.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

2.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

3.  Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

Authors:  Bénédicte Foveau; Frédéric Ancot; Catherine Leroy; Annalisa Petrelli; Karina Reiss; Valérie Vingtdeux; Silvia Giordano; Véronique Fafeur; David Tulasne
Journal:  Mol Biol Cell       Date:  2009-03-18       Impact factor: 4.138

4.  Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.

Authors:  Valentina Martin; Simona Corso; Paolo M Comoglio; Silvia Giordano
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

5.  Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Authors:  Razelle Kurzrock; Steven I Sherman; Douglas W Ball; Arlene A Forastiere; Roger B Cohen; Ranee Mehra; David G Pfister; Ezra E W Cohen; Linda Janisch; Forlisa Nauling; David S Hong; Chaan S Ng; Lei Ye; Robert F Gagel; John Frye; Thomas Müller; Mark J Ratain; Ravi Salgia
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

6.  Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.

Authors:  Ken Suzawa; Michael Offin; Daniel Lu; Christopher Kurzatkowski; Morana Vojnic; Roger S Smith; Joshua K Sabari; Huichun Tai; Marissa Mattar; Inna Khodos; Elisa de Stanchina; Charles M Rudin; Mark G Kris; Maria E Arcila; William W Lockwood; Alexander Drilon; Marc Ladanyi; Romel Somwar
Journal:  Clin Cancer Res       Date:  2018-10-23       Impact factor: 12.531

Review 7.  The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.

Authors:  Kim Moran-Jones
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

8.  Resistance of papillary thyroid cancer stem cells to chemotherapy.

Authors:  Raffaella Giuffrida; Luana Adamo; Gioacchin Iannolo; Luisa Vicari; Dario Giuffrida; Adriana Eramo; Massimo Gulisano; Lorenzo Memeo; Concetta Conticello
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

9.  In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Authors:  Frauke Bentzien; Marcus Zuzow; Nathan Heald; Anna Gibson; Yongchang Shi; Leanne Goon; Peiwen Yu; Stefan Engst; Wentao Zhang; Donghui Huang; Lora Zhao; Valentina Vysotskaia; Felix Chu; Rajana Bautista; Belinda Cancilla; Peter Lamb; Alison H Joly; F Michael Yakes
Journal:  Thyroid       Date:  2013-09-17       Impact factor: 6.568

Review 10.  Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.

Authors:  V Finisguerra; H Prenen; M Mazzone
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.